Rawan Tarawneh Laboratory

Overview:

The Tarawneh Biomarker Discovery Laboratory is dedicated to the identification of novel fluid biomarkers for neurological disorders with a focus on AD and other neurodegenerative disorders. We employ bioinformatics and iPSC research for novel biomarker and drug target discovery. Our team has experience in the development and validation of immunoassays for reliable protein, DNA, and RNA biomarker measurements using state-of-the-art PCR, proximity ligation assays (PLA), and SIMOA technologies. We also utilize human iPSCs to study AD disease mechanisms and identify new targets for drug development.

Breakthrough Research:

-Identifying novel markers of neuronal and synaptic injury in AD

-Identifying novel markers of brain endothelial injury in AD, TBI, ischemic brain injury, and COVID-19

-Identifying novel markers for neuronal-glial-endothelial interactions in AD

Current Projects:

1. Discovery and Validation of Novel Synaptic Markers for Neurodegenerative Disorders

2. MicroRNAs as Biomarkers of Alzheimer Disease and Frontotemporal Dementia

3. Elucidating the Role of Endothelial Injury in Neuronal and Synaptic Degeneration

4. Utilizing human iPSC cell lines for biomarker and drug target discovery in AD and ADRD